{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:45:22Z","timestamp":1790239522836,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005313","name":"Barts and The London School of Medicine and Dentistry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 inflammasome activation, two key components in the pathophysiology of sepsis and sepsis-associated cardiac dysfunction. In this study we investigated whether pharmacological inhibition of BTK (ibrutinib 30 mg\/kg and acalabrutinib 3 mg\/kg) attenuates sepsis associated cardiac dysfunction in mice. 10-week old male C57BL\/6 mice underwent CLP or sham surgery. One hour after surgery mice received either vehicle (5% DMSO + 30% cyclodextrin i.v.), ibrutinib (30 mg\/kg i.v.), or acalabrutinib (3 mg\/kg i.v.). Mice also received antibiotics and an analgesic at 6 and 18 h. After 24 h, cardiac function was assessed by echocardiography <jats:italic>in vivo<\/jats:italic>. Cardiac tissue underwent western blot analysis to determine the activation of BTK, NLRP3 inflammasome and NF-\u03baB pathway. Serum analysis of 33 cytokines was conducted by a multiplex assay. When compared to sham-operated animals, mice subjected to CLP demonstrated a significant reduction in ejection fraction (EF), fractional shortening (FS), and fractional area change (FAC). The cardiac tissue from CLP mice showed significant increases of BTK, NF-\u03baB, and NLRP3 inflammasome activation. CLP animals resulted in a significant increase of serum cytokines and chemokines (TNF-\u03b1, IL-6, IFN-\u03b3, KC, eotaxin-1, eotaxin-2, IL-10, IL-4, CXCL10, and CXCL11). Delayed administration of ibrutinib and acalabrutinib attenuated the decline of EF, FS, and FAC caused by CLP and also reduced the activation of BTK, NF-\u03baB, and NLRP3 inflammasome. Both ibrutinib and acalabrutinib significantly suppressed the release of cytokines and chemokines. Our study revealed that delayed intravenous administration of ibrutinib or acalabrutinib attenuated the cardiac dysfunction associated with sepsis by inhibiting BTK, reducing NF-\u03baB activation and the activation of the inflammasome. Cytokines associated with sepsis were significantly reduced by both BTK inhibitors. Acalabrutinib is found to be more potent than ibrutinib and could potentially prove to be a novel therapeutic in sepsis. Thus, the FDA-approved BTK inhibitors ibrutinib and acalabrutinib may be repurposed for the use in sepsis.<\/jats:p>","DOI":"10.3389\/fimmu.2019.02129","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:39:39Z","timestamp":1567780779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["RETRACTED: Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice"],"prefix":"10.3389","volume":"10","author":[{"given":"Caroline E.","family":"O'Riordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth S. D.","family":"Purvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Collotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Chiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Wissuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sura","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Stiehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina M.","family":"Coldewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Collino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thiemermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","article-title":"Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations","volume":"193","author":"Fleischmann","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/jac\/dkq515","article-title":"Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective)","volume":"66","author":"Daniels","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"B4","unstructured":"RichardsM\n          Sepsis Management as an NHS Clinical Priority2014"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/bja\/aep339","article-title":"Sepsis and the heart","volume":"104","author":"Hunter","year":"2010","journal-title":"Br J Anaesth."},{"key":"B6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.7326\/0003-4819-113-3-227","article-title":"Septic shock in humans","volume":"113","author":"Parrillo","year":"1990","journal-title":"Ann Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0300-9572(96)90072-6","article-title":"Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum","volume":"183","author":"Kumar","year":"1996","journal-title":"J Exp Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.chest.2018.08.1037","article-title":"The septic heart: current understanding of molecular mechanisms and clinical implications","volume":"155","author":"Martin","year":"2019","journal-title":"Chest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell."},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2015.02.019","article-title":"Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice","volume":"15","author":"Sanford","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs."},{"key":"B12","unstructured":"Imbruvica2019"},{"key":"B13","unstructured":"Orphan designation: Acalabrutinib for: Treatment of Chronic Lymphocytic Leukaemia\/Small Lymphocytic Lymphoma2016"},{"key":"B14","unstructured":"Orphan Designation: Acalabrutinib for: Treatment of Lymphoplasmacytic Lymphoma2016"},{"key":"B15","unstructured":"Orphan Designation: Acalabrutinib for: Treatment of Mantle Cell Lymphoma2016"},{"key":"B16","doi-asserted-by":"publisher","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J Biol Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaci.2017.01.017","article-title":"Human NACHT, LRR, and PYD domain\u2013containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase","volume":"140","author":"Liu","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41598-017-00482-4","article-title":"Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1242\/dmm.011528","article-title":"Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure","volume":"6","author":"Collino","year":"2013","journal-title":"Dis Model Mech."},{"key":"B22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2003.11.017","article-title":"Cytometric bead array: a multiplexed assay platform with applications in various areas of biology","volume":"110","author":"Morgan","year":"2004","journal-title":"Clin Immunol."},{"key":"B23","first-page":"125","article-title":"Bead-based multianalyte flow immunoassays","volume-title":"Methods in Molecular Biology","author":"Varro","year":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"4396368","DOI":"10.1155\/2016\/4396368","article-title":"The CXCL10\/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart","volume":"2016","author":"Altara","year":"2016","journal-title":"J Immunol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12265-016-9703-3","article-title":"CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study","volume":"9","author":"Altara","year":"2016","journal-title":"J Cardiovasc Transl Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0141394","DOI":"10.1371\/journal.pone.0141394","article-title":"Left ventricular dysfunction and CXCR3 ligands in hypertension: from animal experiments to a population-based pilot study","volume":"10","author":"Altara","year":"2015","journal-title":"PLoS ONE."},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-065X.2000.00605.x","article-title":"Regulation of the phospholipase C-gamma2 pathway in B cells","volume":"176","author":"Kurosaki","year":"2000","journal-title":"Immunol Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00024382-200014020-00007","article-title":"Activation of NF-kappaB varies in different regions of the gastrointestinal tract during endotoxemia","volume":"14","author":"Pritts","year":"2000","journal-title":"Shock."},{"key":"B29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0026-895X(24)23027-3","article-title":"Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs","volume":"55","author":"Liu","year":"1999","journal-title":"Mol Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3389\/fimmu.2018.02996","article-title":"Linagliptin attenuates the cardiac dysfunction associated with experimental sepsis in mice with Pre-existing Type 2 diabetes by inhibiting NF-\u03baB","volume":"9","author":"Al Zoubi","year":"2018","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1681\/ASN.2015060670","article-title":"I\u03baB Kinase inhibitor attenuates sepsis-induced cardiac dysfunction in CKD","volume":"28","author":"Chen","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e85834","DOI":"10.1371\/journal.pone.0085834","article-title":"Btk regulates macrophage polarization in response to lipopolysaccharide","volume":"9","author":"N\u00ed Gabhann","year":"2014","journal-title":"PLoS ONE."},{"key":"B33","first-page":"669","article-title":"Role of cytokines as a double-edged sword in sepsis","volume":"27","author":"Chaudhry","year":"2013","journal-title":"In Vivo."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1084\/jem.170.5.1627","article-title":"Antibodies to cachectin\/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia","volume":"170","author":"Fong","year":"1989","journal-title":"J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature01326","article-title":"The immunopathogenesis of sepsis","volume":"420","author":"Cohen","year":"2002","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e107639","DOI":"10.1371\/journal.pone.0107639","article-title":"Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1164\/rccm.201604-0892OC","article-title":"NLRP3 Inflammasome deficiency protects against microbial sepsis via increased Lipoxin B4 synthesis","volume":"196","author":"Lee","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1164\/rccm.201308-1535OC","article-title":"Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock","volume":"189","author":"Berghe","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1073\/pnas.041611398","article-title":"Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta","volume":"98","author":"Pomerantz","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7163057","article-title":"miR-146a attenuates sepsis-induced myocardial dysfunction by suppressing IRAK1 and TRAF6 via targeting ErbB4 expression","volume":"2018","author":"An","year":"2018","journal-title":"Oxid Med Cell Longev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e103734","DOI":"10.1371\/journal.pone.0103734","article-title":"MyD88-, but not Nod1- and\/or Nod2-deficient mice, show increased susceptibility to polymicrobial sepsis due to impaired local inflammatory response","volume":"9","author":"S\u00f4nego","year":"2014","journal-title":"PLoS ONE."}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1561869","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"record-id":"62577"},{"DOI":"10.3389\/fimmu.2025.1561869","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2019.02129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T08:43:41Z","timestamp":1737967421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2019.02129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2019.02129"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02129","relation":{"retraction":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1561869","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"article-number":"2129"}}